Hypothesis driven drug design: Improving quality and effectiveness of the design-make-test-analyse cycle

Drug Discovery Today

Volumn 17, Issue 1-2, 2012, Pages 56-62

  Plowright, Alleyn T ^a   Johnstone, Craig ^b   Kihlberg, Jan ^a   Pettersson, Jonas ^a   Robb, Graeme ^b   Thompson, Richard A ^a  

^a ASTRAZENECA R AND D   (Sweden)

^b ASTRAZENECA   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

DATA BASE; DESIGN MAKE TEST ANALYSE CYCLE; DRUG DESIGN; DRUG DEVELOPMENT; DRUG PURIFICATION; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; TOTAL QUALITY MANAGEMENT; WORKFLOW; WORKING TIME;

DRUG DESIGN; DRUG INDUSTRY; HUMANS; PHARMACEUTICAL PREPARATIONS;

EID: 84863393476     PISSN: 13596446     EISSN: 18785832     Source Type: Journal    
DOI: 10.1016/j.drudis.2011.09.012     Document Type: Review

References (34)

1. S. Andersson Making medicinal chemistry more effective - application of Lean Sigma to improve processes, speed and quality Drug Discov. Today 14 2009 598 604
2. P. Barton From crude samples to highly pure isolated solids in 4 hours Chromatogr. Today 2010 26 29
3. F. Ullman, and R.A. Boutellier A case study of lean drug discovery: from project driven research to innovation studios and process factories Drug Discov. Today 13 2008 543 550
4. D. Reinertsen, and L. Shaeffer Making R&D lean Res. Technol. Manage. 48 2005 51 57
5. S.F.J. Macdonald, and P.W. Smith Lead optimisation in 12 months? True confessions of a chemistry team Drug Discov. Today 6 2001 947 953 (Pubitemid 32799252)
6. T. O'Reilly What is Web 2.0: design patterns and business models for the next generation of software Commun. Strat. 1 2007 17 37
7. M.D. Brodney Project-focused activity and knowledge tracker: a unified data analysis, collaboration, and workflow tool for medicinal chemistry project teams J. Chem. Inf. Model. 49 2009 2639 2649
8. G. Robb Hypothesis-driven Drug Design using Wiki-based Collaborative Tools 2009 UK QSAR & Chemoinformatics, Spring Meeting
9. H. van den Waterbeemd, and E. Gifford ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. 2 2003 192 204 (Pubitemid 37361664)
10. C.A. Lipinski Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Deliv. Rev. 23 1997 3 25 (Pubitemid 27046991)
11. D.F. Veber Molecular properties that influence the oral bioavailability of drug candidates J. Med. Chem. 45 2002 2615 2623 (Pubitemid 34595232)
12. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision making in medicinal chemistry Nat. Rev. Drug Discov. 6 2007 881 890 (Pubitemid 350042396)
13. J.D. Hughes Physicochemical drug properties associated with in vivo toxicological outcomes Bioorg. Med. Chem. Lett. 18 2008 4872 4875
14. M.P. Gleeson Generation of a set of simple, interpretable ADMET rules of thumb J. Med. Chem. 51 2008 817 834 (Pubitemid 351304691)
15. M.J. Waring Lipophilicity in drug discovery Expert Opin. Drug Discov. 5 2010 235 248
16. H. Zhao Lead optimization in the nondrug-like space Drug Discov. Today 16 2011 158 163
17. W. Redfern Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development Cardiovasc. Res. 58 2003 32 45 (Pubitemid 36351620)
18. T.W.J. Cooper Factors determining the selection of organic reactions by medicinal chemists and the use of these reactions in arrays (small focused libraries) Angew. Chem. Int. Ed. 49 2010 2 12
19. S.A. Roberts High-throughput screening approaches for investigating drug metabolism and pharmacokinetics Xenobiotica 31 2001 557 589 (Pubitemid 32826392)
20. C.M. Masimirembwa In vitro high throughput screening of compounds for favorable metabolic properties in drug discovery Comb. Chem. High Throughput Screen 4 2001 245 263 (Pubitemid 32433637)
21. D.B. Kassel Applications of high-throughput ADME in drug discovery Curr. Opin. Chem. Biol. 8 2004 339 345 (Pubitemid 38759410)
22. T.N. Thompson Optimization of metabolic stability as a goal of modern drug design Med. Res. Rev. 21 2001 412 449 (Pubitemid 32751463)
23. M. MacCoss, and T.A. Baillie Organic chemistry in drug discovery Science 303 2004 1810 1813 (Pubitemid 38374865)
24. W.A. Korfmacher Advances in the integration of drug metabolism into the lead optimization paradigm Mini Rev. Med. Chem. 9 2009 703 716
25. L. Di, and E.H. Kerns Application of pharmaceutical profiling assays for optimization of drug-like properties Curr. Opin. Drug Discov. Dev. 8 2005 495 504 (Pubitemid 40917411)
26. S. Braggio Drug efficiency: a new concept to guide lead optimization programs towards the selection of better clinical candidates Expert Opin. Drug Discov. 5 2010 609 618
27. M.P. Gleeson Probing the links between in vitro potency, ADMET and physicochemical parameters Nat. Rev. Drug Discov. 10 2011 197 208
28. A.G. Leach Matched molecular pairs as a guide in the optimization of pharmaceutical properties: a study of aqueous solubility, plasma protein binding and oral exposure J. Med. Chem. 49 2006 6672 6682 (Pubitemid 44749735)
29. M. Gladwell Outliers: The Story of Success 2008 Little, Brown and Company
30. D.K. Agrafiotis Recent advances in chemoinformatics J. Chem. Inf. Model. 47 2007 1279 1293 (Pubitemid 47214446)
31. T.J. Ritchie The graphical representation of ADME-related molecule properties for medicinal chemists Drug Discov. Today 16 2011 65 72
32. J.P. Kotter Leading Change 1995 Harvard Business Press
33. S.M. Walker, and B.J. Davies Deploying continuous improvement across the drug discovery value chain Drug Discov. Today 16 2011 467 471
34. C. Johnstone Creativity, innovation and lean sigma: a controversial combination? Drug Discov. Today 16 2011 50 57